Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
320
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Matthew M. Leia Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA;b Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-5348-6065View further author information
ORCID Icon,
Mark N. Soriala Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA;b Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USAView further author information
,
Uvette Loua Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA;b Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USAView further author information
,
Michelle Yuc School of Pharmacy, Northeastern University, Boston, MA, USAView further author information
,
Andrea Medranoc School of Pharmacy, Northeastern University, Boston, MA, USAView further author information
,
Josie Fordb Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USAORCID Iconhttps://orcid.org/0009-0004-7612-3258View further author information
ORCID Icon,
Ronald A. Nemecb Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USAView further author information
,
Jeremy S. Abramsonb Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-8467-9257View further author information
ORCID Icon &
Jacob D. Soumeraib Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3062-6819View further author information
ORCID Icon show all
Pages 653-659 | Received 27 Nov 2023, Accepted 21 Jan 2024, Published online: 31 Jan 2024

References

  • Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa1815281
  • Eichhorst B, Niemann C, Kater AP, et al. A randomized phase III study of venetoclax-Based time-limited combination treatments (RVe, GVe, GIVe) Vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First Co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. Blood. 2021;138(Suppl 1):71–71. doi:10.1182/blood-2021-146161
  • Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34(2):324–356. doi:10.1007/s12325-016-0451-1
  • Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765–2775. doi:10.1182/blood-2019-01-896290
  • Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25(14):4264–4270. doi:10.1158/1078-0432.CCR-19-0361
  • Koehler AB, Leung N, Call TG, et al. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020;61(10):2383–2388. doi:10.1080/10428194.2020.1768384
  • Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854. doi:10.1056/NEJMra0904569
  • Yang Y, Shu Y, Chen G, et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for venetoclax. PLoS One. 2022;17(12):e0278725. doi:10.1371/journal.pone.0278725
  • Seymour JF, Gribben JG, Davids MS, et al. Assessment of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the clinical trial and post-Marketing settings. Blood. 2020;136(Supplement 1):37–38. doi:10.1182/blood-2020-134938
  • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976
  • Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. Hematological Oncology. 2023;41(S2):58–60. doi:10.1002/hon.3163_25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.